Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inbox Gmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscription Click this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
For Your Education and Enjoyment 3 Healthcare Companies Insiders Are Buying Written by Thomas Hughes. Published 10/14/2025. 
Key Points - Shoulder Innovations insiders are buying with revenue expected to blossom over the coming years.
- Camp4 Therapeutics was affirmed by a cash injection and analyst upgrade.
- Eli Lilly insiders buy the dip, indicating a value is present.
Healthcare companies are among the riskiest investments because of product development failure and market disruptions. They can also deliver attractive returns—if you pick the right ones. Insider buying isn't a guarantee of explosive results, but it can be a useful signal. Below are three healthcare companies whose insiders are buying shares, and not solely to support the stock price. These companies all have potential to deliver for investors through their therapies and to impact global health outcomes. Shoulder Innovations Insiders Signal Confidence in Revenue Outlook George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert.
He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves. Click here to see what's coming before the story goes mainstream. Shoulder Innovations (NYSE: SI) is a small med-tech company that went public via an IPO in 2025. The company manufactures advanced shoulder replacement systems and is already generating revenue. Although still early-stage, it is expected to grow at a solid double-digit pace over the next few years, and analysts may be underestimating its market position. The global shoulder replacement market is valued at more than $2.2 billion in 2025 and is expected to grow by roughly 50% by 2030. Analysts' forecasts assume Shoulder Innovations will capture only 2% to 3% of that market as of mid-October 2025. Insiders are buying Shoulder Innovations. InsiderTrades data shows numerous insider purchases by the CEO, CFO, board members and a major shareholder. That major shareholder is Gilde Healthcare Holdings, BV, listed as a 10% owner; Gilde is a health-focused private investment group with offices in the U.S. and Germany. Institutional ownership was above 65% in Q4 2025, indicating a solid support base. InsiderTrades tracks coverage from six analysts, which includes a Moderate Buy rating and a consensus forecast implying roughly 62% upside. 
Camp4 Therapeutics Corporation—The Outlook Brightens Camp4 Therapeutics Corporation (NASDAQ: CAMP) saw insider purchases in Q3 from the CEO, CFO, directors and a major shareholder. Those buys coincided with a cash injection, advances in the pipeline, an improved revenue outlook and an analyst upgrade. Insiders and major shareholders collectively own more than 30% of the company and have helped reverse the stock's decline. Institutional support is also strong, with fund and wealth managers, private equity and venture capital firms holding nearly all of the remaining shares. Camp4's primary focus is an RNA-based SYNGAP1 therapy for genetic disorders. The company previously faced delisting risk, which has been averted for now. Analyst sentiment has turned more positive, including an upgrade from Zacks Investment Research to a #2 (Buy) rating, citing upward revenue revisions. Forecasts suggest Camp4 could grow revenue at a very high compound annual rate over the next five to ten years. 
Eli Lilly Insiders Buy After a Long Period of Only Selling Eli Lilly (NYSE: LLY) saw insider purchases in Q3 — the first meaningful buying after several years of predominantly insider selling. Buyers included multiple directors, the CEO and an executive vice president, signaling broad-based confidence. Eli Lilly's industry-leading GLP-1 therapies and the value that emerged after a sharp sell-off (more than 30% below 2024 highs) are among the reasons for the buying. Institutions, however, have been selling into the Q3/Q4 rally, which poses a risk. Institutions own more than 80% of the stock and could limit near-term gains until that selling tide reverses. Upcoming earnings releases and analyst updates could help trigger that shift. Revenue and earnings forecasts have been trimmed, which may position the company to outperform expectations. Sentiment remains generally bullish: price-target reductions contributed to the correction, but analyst sentiment holds at Moderate Buy. The downtrend in price revisions ended in Q3, and the consensus—which began edging higher in Q3—now implies about a 17% upside. 
| 
Post a Comment
Post a Comment